

Sebastiano Intagliata, Ph.D.

Associate Professor of Medicinal Chemistry

Department of Drug and Health Sciences

University of Catania

Viale A. Doria 6, 95125 Catania, Italy.

Phone: +39-095-738-4053

E-mail: s.intagliata@unict.it

Skype: s.intagliata

Website: <http://www.dsf.unict.it/docenti/sebastiano.intagliata>**Scopus** Author ID: [56328031500](https://orcid.org/0000-0002-0201-1745)<http://orcid.org/0000-0002-0201-1745>

PERSONAL INFORMATION

Date of birth: 10/09/1987

Place of birth: Siracusa

Nationality: Italian

BIBLIOMETRIC DATA (source Scopus)

Total number of publications: 52

Total number of citations: 1075

h-index: 21**EDUCATION**

Jan. 2013 – Feb. 2016 Doctor of Philosophy in Pharmaceutical Sciences, Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy. Dissertation title: "New alkylpiperazines as 5-HT₇R ligands". Advisor: Prof. Maria N. Modica.

Jan. 2013 Qualified as a Pharmacist in Italy.

Oct. 2006 – July 2012 Master degree in chemistry and Pharmaceutical Technology, Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy. Dissertation title: "New quinazoline derivatives as potential 5-HT₇R ligands". Advisor: Prof. Maria N. Modica.

RESEARCH EXPERIENCE

Jul. 2025 – present Associate Professor of Medicinal Chemistry (ssd CHEM-07/A), Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy. Project description: development of novel 5-fluorouracil-based mutual prodrugs as novel anticancer drugs. Design and synthesis of new σ receptor ligands. Design and synthesis of new HO-1 inhibitors.

Jul. 2022 – Jun. 2025 Assistant Professor (RTD-b) of Medicinal Chemistry, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy. Project description: development of novel heme oxygenase 1 (HO-1)

inhibitors-based mutual prodrugs as innovative approach in anticancer chemotherapy. Design and synthesis of new σ receptor ligands. Design and synthesis of new HO-1 inhibitors.

- Feb. 2022 National Scientific qualification as Associate Professor of Medicinal Chemistry in the Italian higher education system for the disciplinary field 03/D1 - Medicinal, toxicological and nutritional chemistry and applied technologies.
- Aug. 2019 – Jun. 2022 Research Associate (RTD-a), Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy. Project description: design and synthesis of novel multi-target ligands with anticancer activity, as innovative approach to overcome drug resistance in cancer chemotherapy.
- Oct. 2020 – Feb. 2021 Visiting Researcher, Department of Organic Chemistry, Jagiellonian University Medical College. Supervisor: Prof. dr hab. Paweł Zajdel. Project description: *in vitro* chemical and metabolic assessment of new 5-FU/HO-1 inhibitor hybrids as potential anticancer drugs.
- Jan. 2020 – Feb. 2020 Visiting Researcher, Department of Molecular Medicine and Princess Al-Jawhara Center for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain. Supervisor: Prof. Khaled Greish. Project description: *in vitro* pharmacological evaluation, and nanoformulation testing of new heme oxygenase-1 inhibitors, and their hybrid analogs with anticancer drugs
- Jan. 2017 – June 2019 Post-Doctoral Associate, Department of Medicinal Chemistry, College of Pharmacy, University of Florida. Gainesville, FL, USA. Supervisor: Prof. Christopher R. McCurdy. Project description: lead optimization of a highly selective sigma-1 receptor antagonist; design and synthesis of sigma receptor ligands as potential treatments for pain and drug abuse.
- May 2016 – Jan. 2017 Post-Doctoral Associate, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, Oxford, MS, USA. Supervisor: Christopher R. McCurdy. Project description: design and synthesis of sigma receptor ligands, and opioid derivatives.
- July 2015 – Sept. 2015 Visiting scholar working, University of Mississippi, Oxford, MS, USA. Supervisor: Christopher R. McCurdy, Ph.D. Project description: design and synthesis of new benzo[d]thiazol-2(3H)one based sigma-1 receptor ligands.
- Jan. 2015 – May 2015 Visiting PhD Student, Institute of Pharmacology of the Polish Academy of Sciences, Department of Medicinal Chemistry, Krakow, Poland. Supervisor: Prof. Andrzej J. Bojarski. Project description: homology modeling of G-protein-coupled receptors, virtual screening, ligand docking, pharmacophore modeling, theoretical conformational analysis, prediction of physico-chemical, and pharmacokinetic properties of chemical compounds, *in silico* studies of ligand-receptor interactions

RESEARCH INTERESTS

Currently, my research is focused on the design, and synthesis of novel heme oxygenase 1 (HO-1) inhibitors with peculiar anticancer activity, as well as the development of hybrid compounds obtained by combining the structure of imidazole-based HO-1 inhibitors with sigma receptor ligands and/or anticancer drugs, as an innovative approach to overcome drug resistance as well as to improve cancer chemotherapy. My research interests include drug discovery, structure-based drug design, hit to lead optimization, organic synthesis.

GRANT FUNDING

- Project “A double hybrids strategy for cancer treatment by targeting the heme oxygenase system (HO-Hybrid2, code P2022F4PTE, CUP Master E53D23015960001, granted to S.I), through the National Recovery and Resilient Plan (PNRR) Mission 4, Component 2, Investment 1.1, call for tender “Bando PRIN 2022 PNRR” No. 1409, published on 14/09/2022 by the Italian Ministry of University and Research (MUR), funded by European Union - NexGenerationEU plan. Role: Principal investigator, budget 239.999 €.
- Piano di incentivi per la ricerca di Ateneo 2020/2022 (Pia.ce.ri.), linea di Intervento 3 “Starting Grant”. Title: Novel polypharmacological agents as innovative cancer treatments, POLYPHARMA-CT. Role: Principal investigator, budget € 5000/year (two years).

PARTECIPATION IN RESEARCH PROJECTS

- PIAno di inCentivi per la Ricerca di Ateneo 2024/2026”, Titolo: “INhibitors of heme Oxygenase as noVel therApeutics (INOVA)”, linea di intervento 1, *Principal investigator*: Prof. Giuseppe Romeo; role: research personnel.
- PON R&I funds 2014-2020, CUP: E66C18001320007, AIM1872330, activity 1. Title: New strategies for the development of anticancer agents. Principal Investigator: Prof. Rosario Pignatello, role: research personnel.
- Piano di incentivi per la ricerca di Ateneo 2020/2022 (Pia.ce.ri.). Title: Modulazione dell’Eme ossigenasi nella Terapia Antitumorale, META. Principal investigator: Prof. Valeria Pittalà, role: research personnel.
- United States Department of Defense DoD, PR161310, contract W81XWH-17-1-0557. Title: Sigma receptor ligands and non-opioid based pain management. Principal Investigators: Christopher McCurdy, Ph.D., FAAPS, and Jay P. McLaughlin, Ph.D., role: research personnel
- FIR 2014 (Finanziamento Ricerca di Ateneo) University of Catania, contract 764AAD. Title: Antioxidants loaded lipid nano-carriers for the treatment of neurodegenerative diseases based on mitochondrial disorders. Principal Investigator: Prof. Giovanni Puglisi, role: research personnel.

PATENTS

International patent WO2024/138108, Title: “METABOLICALLY STABLE SIGMA RECEPTOR LIGANDS”

- *Publication Date*: 27/06/2024
- *International Application No.* PCT/US2023/085639 (based on US Patent Application No.: 63/434848)
- *International Filing Date*: 22/12/2023
- *Inventors*: Christopher R. McCurdy, Hebaalla M. Agha, Sebastiano Intagliata.

PUBLICATIONS

1. **Intagliata, S.**; Ciaffaglione, V.; Consoli, V.; D'Amico, G.; Vanella, L.; Pittalà, V.; Sodano, F.; Albrizio, S.; Sorrenti, V.; Salerno, L. Combination of heme oxygenase-1 inhibitors and temozolomide to improve the anticancer effect in glioblastoma. *Eur. J. Med. Chem. Rep.*, **2024**, 12, 100227.
2. Consoli, V.; Fallica, A.N.; Virzi, N.F.; Salerno, L.; **Intagliata, S.**; Sorrenti, V.; Greish, K.; Giuffrida, A.; Vanella, L.; Pittalà, V. Synthesis and in Vitro Evaluation of CAPE Derivatives as Ferroptosis Inducers in Triple Negative Breast Cancer. *ACS Med Chem Lett.* **2024**, 15, 706-713. doi: 10.1021/acsmmedchemlett.4c00099.
3. Salerno, L.; Notaro, A.; Consoli, V.; Affranchi, F.; Pittalà, V.; Sorrenti, V.; Vanella, L.; Giuliano, M.; **Intagliata, S.** Evaluation of the anticancer effects exerted by 5-fluorouracil and heme oxygenase-1 inhibitor hybrids in HTC116 colorectal cancer cells. *J Enzyme Inhib Med Chem.* **2024**, 39, 2337191. doi: 10.1080/14756366.2024.2337191.
4. Ali Alghamdi, M.; Haider, M.; **Intagliata, S.**; Pittalà, V.; Jagal, J.; Haider, Y.; Althaf, N.; Greish, K.; Lauric acid-based thermosensitive delivery system for the treatment of head and neck squamous cell carcinoma. *J Drug Target.* **2024**, 32, 433-443. doi: 10.1080/1061186X.2024.2323056.
5. Suárez-Rojas, I.; Pérez-Fernández, M.; Bai, X.; Martínez-Martel, I.; **Intagliata, S.**; Pittalà, V.; Salerno, L.; Pol, O. The Inhibition of Neuropathic Pain Incited by Nerve Injury and Accompanying Mood Disorders by New Heme Oxygenase-1 Inducers: Mechanisms Implicated. *Antioxidants.* **2023**, 12, 1859. doi: 10.3390/antiox12101859.
6. Salerno, L. et al. Discovery of SI 1/20 and SI 1/22 as new mutual prodrugs of 5-fluorouracil and imidazole-based heme oxygenase 1 inhibitor with improved cytotoxicity in DU145 prostate cancer cells. *ChemMedChem.* **2023**, Apr 17;18(8):e202300047. doi: 10.1002/cmde.202300047.
7. Nesic de Freitas, L.S.F.; da Silva, C.F.; **Intagliata, S.**; Amata, E.; Salerno, L.; Soeiro, M.N.C. In vitro and in silico analysis of imatinib analogues as anti- Trypanosoma cruzi drug candidates. *Parasitology.* **2023** Jan 12;1-18. doi: 10.1017/S0031182023000057. Online ahead of print.
8. Fallica, A. N.; Ciaffaglione, V.; Modica, M. N.; Pittalà, V.; Salerno, L.; Amata, E.; Marrazzo, A.; Romeo, G.; **Intagliata, S.** Structure-activity relationships of mixed σ_1R/σ_2R ligands with antiproliferative and anticancer effects. *Bioorg. Med. Chem.* **2022**, 73, 117032. doi: 10.1016/j.bmc.2022.117032.
9. Wilson, L.L.; Alleyne, A.R.; Eans, S.O.; Cirino, T.J.; Stacy, H.M.; Mottinelli, M.; **Intagliata, S.**; McCurdy, C.R.; McLaughlin JP. Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. *Molecules.* **2022**, 27, 3617. doi: 10.3390/molecules27113617.
10. Ciaffaglione, V.; Consoli, V.; **Intagliata, S.**; Marrazzo, A.; Romeo, G.; Pittalà, V.; Greish, K.; Vanella, L.; Floresta, G.; Rescifina, A.; Salerno, L.; Sorrenti V. Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. *Molecules.* **2022**, 27, 3220. doi: 10.3390/molecules27103220.
11. Consoli, V.; Sorrenti, V.; Pittalà, V.; Greish, K.; D'Amico, A.G.; Romeo, G.; **Intagliata, S.**; Salerno, L.; Vanella, L. Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells. *Int. J. Mol. Sci.* **2022**, 23, 5709. doi: 10.3390/ijms23105709.
12. Elkholy, N.; Abdelwaly, A.; Mohamed, K.; Amata, E.; Lombino, J.; Cosentino, G.; **Intagliata, S.**; Helal, M.A. Discovery of 3-(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligands. *Chem. Biol. Drug. Des.* **2022**, 100, 25-40. doi: 10.1111/cbdd.14047.
13. Popa, R.; Kamble, S.H.; Kanumuri, R.S.; King, T.I.; Berthold, E.C.; **Intagliata, S.**; Sharma, A.; McCurdy, C.R. UPLC-MS/MS method for the quantification of MCI-77, a novel sigma-1 receptor ligand, and its application to pharmacokinetic studies. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **2022**, 1196:123187. doi: 10.1016/j.jchromb.2022.123187.
14. Wilson, L. L.; Eans, S.O.; Ramadan-siraj, I.; Modica, M. N.; Romeo, G.; **Intagliata, S.**; McLaughlin, J.

- P. Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-Allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use. *Int. J. Mol. Sci.*, **2022**, 23, 615. doi: 10.3390/ijms23020615.
15. Puglia, C.; Santonocito, D.; Romeo, G.; **Intagliata, S.**; Romano, G. L.; Stretto, E.; Novelli, E.; Ostacolo, C.; Campiglia, P.; Sommella, E. M.; Pignatello, R.; Bucolo, C. Lipid nanoparticles traverse non-corneal path to reach the posterior eye segment: In vivo evidence. *Molecules*. **2021**, 26, 4673. doi: 10.3390/molecules26154673.
 16. Ciaffaglione, V.; Modica, M. N.; Pittalà, V.; Romeo, G.; Salerno, L.; **Intagliata, S.** Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs. *ChemMedChem*. **2021**, 16, 3496-3512. doi: 10.1002/cmdc.202100473.
 17. Fallica, A. N.; Sorrenti, V.; D'Amico, A. G.; Salerno, L.; Romeo, G.; **Intagliata, S.**; Consoli, V.; Floresta, G.; Rescifina, A.; D'Agata, V.; Vanella, L.; Pittalà, V. Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent in Vitro Antiproliferative Activity. *J. Med. Chem.* **2021**, 64, 13373-13393. doi: 10.1021/acs.jmedchem.1c00633.
 18. Fallica, A.N.; Barbaraci, C.; Amata, E.; Pasquinucci, L.; Turnaturi, R.; Dichiarà, M.; **Intagliata, S.**; Gariboldi, M.B.; Marras, E.; Orlandi, V.T.; Ferroni, C.; Martini, C.; Rescifina, A.; Gentile, D.; Varchi, G.; Marrazzo, A. Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents. *J. Med. Chem.* **2021**, 64, 11597-11613. doi: 10.1021/acs.jmedchem.1c00917.
 19. Romeo, G.; Ciaffaglione, V.; Amata, E.; Dichiarà, M.; Calabrese, L.; Vanella, L.; Sorrenti, V.; Grosso, S.; D'Amico, A.G.; D'Agata, V.; **Intagliata, S.**; Salerno, L. Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity. *Molecules*. **2021**, 26, 3860. doi: 10.3390/molecules26133860.
 20. Giurdanella, G.; Longo, A.; Salerno, L.; Romeo, G.; **Intagliata, S.**; Lupo, G.; Distefano, A.; Platania, C.B.M.; Bucolo, C.; Li Volti, G.; Anfuso, C.D.; Pittalà, V. Glucose-impaired Corneal Re-epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate. *Antioxidants*. **2021**, 10, 831. doi: 10.3390/antiox10060831.
 21. Ben Khalaf, N.; Pham, S.; Romeo, G.; Abdelghany, S.; **Intagliata, S.**; Sedillo, P.; Salerno, L.; Gonzales, J.; Fathallah, D.M.; Perkins, D.J.; Hurwitz, I.; Pittalà, V. A computer-aided approach to identify novel Leishmania major protein disulfide isomerase inhibitors for treatment of leishmaniasis. *J Comput Aided Mol Des*. **2021**, 35, 297-314. doi: 10.1007/s10822-021-00374-w.
 22. Salerno, L.; Vanella, L.; Sorrenti, V.; Consoli, V.; Ciaffaglione, V.; Fallica, A. N.; Canale, V.; Zajdel, P.; Pignatello, R.; **Intagliata, S.** Novel mutual prodrug of 5-fluorouracil and heme oxygenase 1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation. *J. Enzyme Inhib. Med. Chem.* **2021**, 36, 1378-1386. doi: 10.1080/14756366.2021.1928111.
 23. Fallica, A. N.; Pittalà, V.; Modica, M. N.; Salerno, L.; Romeo, G.; Marrazzo, A.; Helal, M.; **Intagliata, S.** Recent Advances in the Development of Sigma Receptors Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. *J. Med. Chem.* **2021**, 64, 7926-7962. doi: 10.1021/acs.jmedchem.0c02265.
 24. Romeo, G.; Bonanno, F.; Wilson, L. L.; Arena, E.; Modica, M.N.; Pittalà, V.; Salerno, L.; Prezzavento, O.; McLaughlin, J. P.; **Intagliata, S.** Development of New Benzylpiperazine Derivatives as σ Receptor Ligands with *in Vivo* Antinociceptive and Anti-allodynic Effects. *ACS Chem. Neurosci.* **2021**, 12, 2003-2012. doi: 10.1021/acschemneuro.1c00106.
 25. **Intagliata, S.**, Spadaro, A., Lorenti, M., Panico, A., Siciliano, E.A., Barbagallo, S., Macaluso, B., Kamble, S.H., Modica, M.N., Montenegro, L. In Vitro Antioxidant and Anti-Glycation Activity of Resveratrol and Its Novel Triester with Trolox. *Antioxidants* **2021**, 10, 12. doi: 10.3390/antiox10010012.
 26. Ianni, F.; Carotti, A.; **Intagliata, S.**; Macchiarulo, A.; Chankvetadze, B.; Pittalà, V.; Sardella, R. Laboratory-Scale Semipreparative Enantioresolution of Phenylethanolic-Azole Heme Oxygenase-1 Inhibitors. *Chromatographia*. **2020**, 83, 1509-1515. doi: 10.1007/s10337-020-03972-2.

27. Popa R.; Kamble, S.H.; Kanumuri, R.S.; King, T.I.; Berthold, E.C.; **Intagliata, S.**; Sharma, A.; McCurdy C.R. Bioanalytical Method Development and Pharmacokinetics of MCI-92, a Sigma-1 Receptor Ligand. *J Pharm Biomed Anal.* **2020**, *191*, 113610. doi: 10.1016/j.jpba.2020.113610.
28. **Intagliata, S.**; Agha, H.; Kopajtic, T.A.; Katz, J.L.; Kamble, S.H.; Sharma, A.; Avery, B.A.; McCurdy, C.R. Exploring 1-Adamantanamine as an Alternative Amine Moiety for Metabolically Labile Azepane Ring in Newly Synthesized Benzo[d]thiazol-2(3*H*)one σ Receptor Ligands. *Med. Chem. Res.*, **2020**, *29*, 1697-1706. doi: 10.1007/s00044-020-02597-2.
29. **Intagliata, S.**; Sharma, A.; King, T.I.; Mesangeau, C.; Seminerio, M.; Chin, F.T.; Wilson, L.L.; Matsumoto, R.R.; McLaughlin, J.P.; Avery, B.A.; McCurdy C.R. Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)butyl)-3-methyl-1*H*-benzo[d]imidazol-2(3*H*)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo. *AAPS J.*, **2020**, *22*, 94. doi: 10.1208/s12248-020-00472-x.
30. Floresta, G.; Carotti, A.; Ianni, F.; Sorrenti, V.; **Intagliata, S.**; Rescifina, A.; Salerno, L.; Di Michele, A.; Sardella, R.; Pittalà, V. Chromatographic resolution of phenylethanol-azole racemic compounds highlighted stereoselective inhibition of heme oxygenase-1 by (R)-enantiomers. *Bioorganic Chemistry*, **2020**, *99*, 103777. doi: 10.1016/j.bioorg.2020.103777.
31. Khan, H.; Pervaiz, A.; Intagliata, S.; Das, N.; Nagulapalli Venkata, K.; Atanasov, A.G.; Najda, A.; Nabavi, S.M.; Wang, D.; Pittalà, V.; Bishayee, A. The analgesic potential of glycosides derived from medicinal plants. *Daru*, **2020**, Feb 14. doi: 10.1007/s40199-019-00319-7.
32. **Intagliata, S.**; Helal, M.A.; Materia, L.; Pittalà, V.; Salerno, L.; Marrazzo, A.; Cagnotto, A.; Salmona, M.; Modica, M.N.; Romeo, G. Synthesis and molecular modelling studies of new 1,3-diaryl-5-oxo-proline derivatives as endothelin receptor ligands. *Molecules*, **2020**, *25*, 185. doi: 10.3390/molecules25081851.
33. Ciaffaglione, V.; **Intagliata, S.**; Pittalà, V.; Marrazzo, A.; Sorrenti, V.; Vanella, L.; Rescifina, A.; Floresta, G.; Sultan, A.; Greish, K.; Salerno, L. New aryethanolimidazole derivatives as HO-1 inhibitors with cytotoxicity against MCF-7 breast cancer cells. *Int. J. Mol. Sci.*, **2020**, *21*, 1923. doi: 10.3390/ijms21061923.
34. **Intagliata, S.**; Salerno, L.; Ciaffaglione, V.; Leonardi, C.; Fallica, A.N.; Carota, G.; Amata, E.; Marrazzo, A.; Pittalà, V.; Romeo, G. Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors. *Eur. J. Med. Chem.*, **2019**, *183*, 111703. doi: 10.1016/j.ejmech.2019.111703.
35. Romeo, G.; Salerno, L.; Pittalà, V.; Candido, M.; **Intagliata, S.**; Amata, E.; Salmona, M.; Cagnotto, A.; Rescifina, A.; Floresta, G.; Modica, M.N. [1]Benzothieno[3,2-*d*]pyrimidine derivatives as ligands for the serotonergic 5-HT₇ receptor. *Eur. J. Med. Chem.*, **2019**, *183*, 111690. doi: 10.1016/j.ejmech.2019.111690.
36. Carota, G.; Raffaele, M.; Sorrenti, V.; Salerno, L.; Pittalà, V.; Intagliata, S. Ginseng and heme oxygenase 1: The link between an old herb and a new protective system. *Fitoterapia*, **2019**, *139*, 104370. doi: 10.1016/j.fitote.2019.104370.
37. **Intagliata, S.**; Modica, M.N.; Santagati, L.M.; Montenegro, L. Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update. *Antioxidants*. **2019**, *8*, 244. doi: 10.3390/antiox8080244.
38. Romeo, G.; Prezzavento, O.; **Intagliata, S.**; Pittalà, V.; Modica, M.N.; Marrazzo, A.; Turnaturi, R.; Parenti, C.; Chiechio, S.; Arena, E.; Campisi, A.; Sposito, G.; Salerno, L. Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands. *Eur. J. Med. Chem.*, **2019**, *174*, 226. doi: 10.1016/j.ejmech.2019.04.056.
39. Sorrenti, V.; Raffaele, M.; Vanella, L.; Acquaviva, R.; Salerno, L.; Pittalà, V.; **Intagliata, S.**; Di Giacomo, C. Protective Effects of Caffeic Acid Phenethyl Ester (Cape) and Novel Cape Analogue as Inducers of Heme Oxygenase-1 in Streptozotocin-Induced Type 1 Diabetic Rats. *Int. J. Mol. Sci.* **2019**, *20*. 2441. doi: 10.3390/ijms20102441.

40. **Intagliata, S.**; Alsharif, W.F.; Mesangeau, C.; Fazio, N.; Seminerio, M.J.; Xu, Y.T.; Matsumoto, R.R.; McCurdy, C.R. Benzimidazolone-based selective σ_2 receptor ligands: Synthesis and pharmacological evaluation. *Eur. J. Med. Chem.*, **2019**, *165*, 250. doi: 10.1016/j.ejmech.2019.01.019.
41. Nicholson, H.E.; Alsharif, W.F.; Comeau, A.B.; Mesangeau, C.; **Intagliata, S.**; Mottinelli, M.; McCurdy, C.R.; Bowen, W.D. Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives. *J. Pharmacol. Exp. Ther.*; **2019**, *368*, 272. doi: 10.1124/jpet.118.253484.
42. Montenegro, L.; Panico, A.M.; Santagati, L.M.; Siciliano, E.A.; **Intagliata, S.**; Modica, M.N. Solid Lipid Nanoparticles Loading Idebenone Ester with Pyroglutamic Acid: In Vitro Antioxidant Activity and In Vivo Topical Efficacy. *Nanomaterials*, **2019**, *9*, 43. doi: 10.3390/nano9010043.
43. Cirino, T.J.; Eans, S.O.; Medina, J.M.; Wilson, L.L.; Mottinelli, M.; **Intagliata, S.**; McCurdy, C.R.; McLaughlin, J.P. Characterization of Sigma 1 Receptor (S1R) antagonist CM-304 and its analog, AZ-66: Novel therapeutics against allodynia and induced pain. *Front. Pharmacol.*, **2019**, *10*, 678. doi: 10.3389/fphar.2019.00678.
44. Pittalà, V.; Vanella, L.; Maria Platania, C.B.; Salerno, L.; Raffaele, M.; Amata, E.; Marrazzo, A.; Floresta, G.; Romeo, G.; Greish, K.; **Intagliata, S.**; Bucolo, C.; Sorrenti, V. Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. *Future Med. Chem.* **2019**, *11*, 1523-1536. doi: 10.4155/fmc-2018-0448.
45. Modica, M.N.; Lacivita, E.; **Intagliata, S.**; Salerno, L.; Romeo, G.; Pittalà, V.; Leopoldo, M. Structure-Activity Relationships and Therapeutic Potentials of 5-HT₇ Receptor Ligands: An Update. *J. Med. Chem.*, **2018**, *61*, 8475. doi: 10.1021/acs.jmedchem.7b01898.
46. Sorrenti, V.; Pittalà, V.; Romeo, G.; Amata, E.; Dichiarà, M.; Marrazzo, A.; Turnaturi, R.; Prezzavento, O.; Barbagallo, I.; Vanella, L.; Rescifina, A.; Floresta, G.; Tibullo D.; Di Raimondo, F.; **Intagliata, S.**; Salerno, L. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines. *Eur. J. Med. Chem.*, **2018**, *158*, 937. doi: 10.1016/j.ejmech.2018.09.048.
47. Greish, K.F.; Salerno, L.; Al Zahrani, R.; Amata, E.; Modica, M.N.; Romeo, G.; Marrazzo, A.; Prezzavento, O.; Sorrenti, V.; Rescifina, A.; Floresta, G.; **Intagliata, S.**; Pittalà, V. Novel Structural Insight into Inhibitors of Heme Oxygenase-1 (HO-1) by New Imidazole-Based Compounds: Biochemical and In Vitro Anticancer Activity Evaluation. *Molecule*, **2018**, *23*, 1209. doi: 10.3390/molecules23051209.
48. **Intagliata, S.**; Modica, M.N.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A.; Salmona, M.; Kurczab, R.; Romeo, G. New *N*- and *O*-arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT₇ and 5-HT_{1A} receptor ligands: Synthesis, structure-activity relationships, and molecular modeling studies. *Bioorg. Med. Chem.*, **2017**, *25*, 1250. doi: 10.1016/j.bmc.2016.12.039.
49. **Intagliata, S.**; Modica, M.N.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A.; Salmona, M.; Romeo, G. Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT₇R selective ligands over 5-HT_{1A}R. *Bioorg. Med. Chem. Lett.*, **2016**, *26*, 4052. doi: 10.1016/j.bmcl.2016.06.080.
50. Modica, M.N.; **Intagliata, S.**; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A.; Salmona, M.; Romeo, G. Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT_{1A} and 5-HT₇ receptor ligands. *Bioorg. Med. Chem. Lett.*, **2015**, *25*, 1427. doi: 10.1016/j.bmcl.2015.02.042.
51. Salerno, L.; Pittalà, V.; Modica, M.N.; Siracusa, M.A.; **Intagliata, S.**; Cagnotto, A.; Salmona, M.; Kurczab, R.; Bojarski, A.J.; Romeo, G. Structure-activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT₇ and 5-HT_{1A} receptor ligands. *Eur. J. Med. Chem.*, **2014**, *85*, 716. doi: 10.1016/j.ejmech.2014.08.023.

INVITED LECTURE

- On-line seminar entitled "Targeting the Heme Oxygenase-1 with Hybrid Compounds as a Novel Anticancer Strategy" on 15th June 2023, during Laboratório de Biologia Celular of the Oswaldo Cruz Institute (IOC/Fiocruz), Rio de Janeiro, Brazil.
- Seminar entitled "Targeting Heme Oxygenase 1 with Imidazole-based Inhibitors to Improve Cancer Chemotherapy" delivered during the Polish Pharmaceutical Society, Krakow Branch Meeting at the Faculty of Pharmacy, Jagiellonian University Medical College on the February 10, **2021**, Krakow, Poland.

ORAL PRESENTATIONS AT SCIENTIFIC MEETINGS

- Salerno, L.; Pittalà, V.; Sorrenti, V.; Vanella, L.; Zajdel, P.; Giuliano, M.; **Intagliata, S.** New 5-fluorouracil and heme oxygenase 1 inhibitor mutual prodrugs with in vitro anticancer activity towards colon cancer cells. AMYC-Biomed 2021, Nov. 3-5, **2021**, Virtual Conference, Med. Chem. Oral Comm. 7.
- Salerno, L.; Ciaffaglione, V.; Vanella, L.; Sorrenti, V.; Consoli, V.; Canale, V.; Zajdel, P.; Giuliano, M.; **Intagliata, S.** Development of Mutual Prodrugs of 5-Fluorouracil and Heme Oxygenase 1 Inhibitor as Anticancer Agents. XXVII Congresso Nazionale della Società Chimica Italiana, Sept. 14-23, **2021**, Virtual Conference, FAR OR028.
- **Intagliata, S.**; Loredana, S.; Pittalà, V.; Modica, M.N.; Arena, E.; Wilson, L.L.; McLaughlin, J.P.; Prezzavento, O.; Romeo, G. Synthesis, binding, and functional properties of new benzylpiperazine derivatives as selective σ_1 receptor ligands. Autumn Meeting for Young Chemists in Biomedical Sciences, Virtual Conference. Oct. 13-14, **2020**.
- **Intagliata, S.**; Wilson, L.; Alleyne, A.; Stacy, H.M.; Kamble, S.H.; Sharma, A.; Cano, J.; Kawesa, T.; Toll, L.; Avery, B.A.; McLaughlin, J.P.; McCurdy, C.R. Novel benzothiazolones and benzoxazolones-based σ receptor ligands: synthesis and preliminary pharmacological evaluation against allodynia. Merck Young Chemists' Symposium. Nov. 25-27, **2019**, Rimini, Italia, OR07.
- **Intagliata, S.**; Wilson, L.; Alleyne, A.; Stacy, H.M.; Kamble, S.H.; Sharma, A.; Cano, J.; Kawesa, T.; Toll, L.; Avery, B.A.; McLaughlin, J.P.; McCurdy, C.R. Synthesis and preliminary pharmacological evaluation of new σ receptor ligands with anti-neuropathic pain effects in mice. 2019 CNPD3 UF Drug Discovery Symposium. Apr. 25-26, **2019**, Gainesville, Florida, USA, pag. 47, 3.
- **Intagliata, S.**; Modica, M.N.; Romeo, G.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto A. New alkylpiperazines as 5-HT₇R ligands. XXV Congresso della Società Chimica Italiana. SCI-2014. Sept. 7-12, **2014**, Arcavacata di Rende, Cosenza, Italia, P-305.

CONTRIBUTIONS AT SCIENTIFIC MEETINGS

- Mocka, S.; Salerno, L.; Pittalà, V.; Modica, M.N.; Consoli, V.; Sorrenti, V.; Sodano, F.; Schiano, M.E.; Vertuccio, S.; Albrizio, S.; Liuzzo, E.; Trapani, M.; Magli, E.; **Intagliata, S.** Synthesis of new 5-fluorouracil and heme oxygenase 1 inhibitor mutual prodrugs with antiproliferative effects. AMYC-BIOMED 2025. Jun. 23-25, **2025**, Palermo, Italy. OS38. *Slide&Talk presentation*
- Mocka, S.; Salerno, L.; Pittalà, V.; Consoli, V.; Sorrenti, V.; Fiorino, F.; Magli, E.; **Intagliata, S.** New mutual prodrugs of 5-fluorouracil and heme oxygenase 1 inhibitor with antiproliferative effects on breast cancer cells. SCISiCa conference, Dec. 2-3, **2024**, Messina, Italy. PO34. *Poster presentation*
- Mocka, S.; Salerno, L.; Pittalà, V.; Consoli, V.; Sorrenti, V.; Fiorino, F.; Magli, E.; **Intagliata, S.** New mutual prodrugs of 5-fluorouracil and heme oxygenase 1 inhibitor with antiproliferative effects on breast cancer cells. SCISiCa conference, Dec. 2-3, **2024**, Messina, Italy. PO34. *Poster presentation*.
- Mocka, S.; Salerno, L.; Pittalà, V.; Consoli, V.; Sorrenti, V.; Fiorino, F.; Magli, E.; **Intagliata, S.**

Development of 5-fluorouracil and heme oxygenase 1 inhibitor mutual prodrugs as an innovative anticancer strategy. First EFMC-YSN Virtual Poster Session, Nov. **2024**, LinkedIn.

- Salerno, L.; Pittalà, V.; Consoli, V.; D'Amico A. G.; Sodano, F.; Schiano, M. E.; Albrizio, S.; Fiorino, F.; Helal, M.A.; **Intagliata, S.** Design, synthesis, and evaluation of dasatinib and heme oxygenase inhibitor hybrids as a novel approach to treat glioblastoma. XXVIII EFMC International Symposium on Medicinal Chemistry, EFMC-ISMIC 2024. Sept. 1-5, **2024**, Roma, Italia. P-281. *Poster presentation*.
- Salerno, L.; Pittalà, V.; Consoli, V.; Sorrenti, V.; Floresta, G.; Fiorino, F.; Magli, E.; **Intagliata, S.** 1,2,4-Triazole-Based Derivatives as Non-Competitive Heme Oxygenase-1 Inhibitors. XVIII Natinal Congressi of the Italian Chemical Society, SCI 2024. Aug. 26-30, **2024**, Milano, Italia. FAR-PO-053. *Poster presentation*.
- Salerno, L.; Ciaffaglione, V.; Pittalà, V.; Modica, M. N.; Romeo, G.; D'Amico A. G.; Consoli, V.; Vanella, L.; Sorrenti, V.; **Intagliata, S.** New dasatinib and heme oxygenase 1 inhibitor hybrids as a novel strategy to treat glioblastoma. 28th National Meeting in Medicinal Chemistry (NMMC28), Sept. 17-20, **2023**, Chieti, Italia. Poster-25. *Poster presentation*.
- **Intagliata, S.**; Ciaffaglione, V.; Pittalà, V.; Romeo, G.; Freitas, L. S. F. N.; Batista, D. G. J.; Batista, M. M.; Costa, K. N.; Soeiro, M. N. C.; and Salerno, L. Synthesis and preliminary in vitro antiparasitic activity against trypanosoma cruzi of new imatinib-based analogs. 28th National Meeting in Medicinal Chemistry (NMMC28), Sept. 17-20, **2023**, Chieti, Italia. Poster-24. *Poster presentation*.
- Fallica, A.; Virzi, N.F.; Floresta, G.; Consoli, V.; **Intagliata, S.**; Romeo, G.; Salerno, L.; Pittalà, V. Recent advances in the discovery of heme oxygenase-1 inhibitors with anticancer activity. 28th National Meeting in Medicinal Chemistry (NMMC28), Sept. 17-20, **2023**, Chieti, Italia. O-C2. *Oral communication*.
- Virzi, N.F.; Fallica, A.; Consoli, V.; Floresta, G.; Salerno, L.; **Intagliata, S.**; Pittalà, V. Development of novel heme oxygenase 1 inhibitors with promising anti-tumoral activity. IX Symposium of Medicinal Chemistry Young Researchers of the Spanish Society of Therapeutic Chemistry (SEQT). June 22, 2023, Santiago de Compostela, Spain. FP10. *Poster presentation*.
- **Intagliata, S.**; Virzi, N.; Fallica, A. N.; Consoli, V.; Vanella, L.; Sorrenti, V.; Salerno, L.; Floresta, G.; Rescifina, A.; Pittalà, V. Development of a ligand-based approach for the identification of new heme oxygenase-1 inhibitors. 27th National Meeting in Medicinal Chemistry (NMMC27), Sept. 11-14, **2022**, Bari, Italia. PO-045. *Poster presentation*.
- Virzi, N.F.; Fallica, A. N.; Sorrenti, V.; Consoli, V.; Burò, I.; Vanella, L.; Salerno, L.; Romeo, G.; **Intagliata, S.**; Pittalà, V. Synthesis and biological evaluation of novel heme oxygenase-1 modulators as potential ferroptosis inducers. 27th National Meeting in Medicinal Chemistry (NMMC27), Sept. 11-14, **2022**, Bari, Italia. PO-079. *Poster presentation*.
- Ciaffaglione, V.; Salerno, L.; Pittalà, V.; Modica, M. N.; Romeo, G.; Marrazzo, A.; Zajdel, P.; Consoli, V.; Sorrenti, V.; Vanella, L.; **Intagliata, S.** Development of 5-fluorouracil and heme oxygenase 1 inhibitor mutual prodrugs as an innovative strategy to develop novel anticancer agents. Workshop Pharmaday 2022, 2^a edizione, June 1, **2022**, Catania, Italia, CFA PO04. *Poster presentation*.
- **Intagliata, S.**; Modica, M. N.; Salerno, L.; Pittalà, V.; Amata, E.; Marrazzo, A.; Wilson, L. L.; McLaughlin, J. P.; Romeo, G. New benzylpiperazine derivatives with high affinity for the sigma-1 receptor and antinociceptive and anti-allodynic effects in vivo. Workshop Pharmaday 2022, 2^a edizione, June 1, **2022**, Catania, Italia, CFA PO04. *Poster presentation*.
- **Intagliata, S.** Wilson, L.L.; Eans, O. S.; Modica, M.N.; Barbaraci, C.; Marrazzo, C.; Romeo, G.; McLaughlin, J.P. Investigation of the antinociceptive and anti-allodynic effects of the sigma-1 receptor ligand SII/28 in mice. Physiopathology of Sigma-1 Receptors, Third European Symposium sponsored by ESTEVE, Oct. 7-9, **2021**, Bari, Italia, Poster 1. *Poster presentation*.
- Barbaraci, C.; Leotta, C. G.; Giurdanella, G.; Longo, A.; **Intagliata, S.**; Pitari, G. M.; Anfusio, D. C.; Amata, E.; Marrazzo, A. Preliminary study of Haloperidol metabolite II valproate ester MRJF22 enantiomers as potential multifunctional agents against uveal melanoma. Physiopathology of Sigma-1 Receptors, Third European Symposium sponsored by ESTEVE, Oct. 7-9, **2021**, Bari, Italia, Oral 21. *Oral presentation*.
- Ciaffaglione, V.; **Intagliata, S.**; de Freitas L.S.F.N., Soeiro, M.N.C.; Salerno, L. New imatinib-based

analogues of benznidazole as anti-*Trypanosoma cruzi* agents for the treatment of Chagas disease. XXVII Congresso Nazionale della Società Chimica Italiana, Sept. 14-23, **2021**, Virtual Conference, FAR PO005. *Poster presentation*.

- Floresta, G.; Fallica, A. N.; Salerno, L.; Sorrenti, V.; **Intagliata, S.**; Rescifina, A.; Pittalà, V. Structure-Guided Fragment-Based Approach to Identify New Heme Oxygenase-1 Inhibitors. XXVII Congresso Nazionale della Società Chimica Italiana, Sept. 14-23, **2021**, Virtual Conference, FAR PO055. *Poster presentation*.
- Romeo, G.; Bonanno, F.; Wilson, L.L.; Arena, E.; Modica, M.N.; Pittalà, V.; Loredana, S.; Prezzavento, O.; McLaughlin, J.P.; **Intagliata, S.** New benzylpiperazines as sigma-1 receptor antagonist with pharmacological effects in mice. 13th Young Medicinal Chemist's Symposium - Nuove Prospettive in Chimica Farmaceutica. Apr. 26-29, **2021**. P38, *Poster presentation*.
- Romeo, G.; Ciaffaglione, V.; Amata, E.; Dichiarà, M.; Consoli, V.; Sorrenti, V.; Grosso, S.; D'Amico, A. G.; **Intagliata, S.**; Salerno, L. Combination of heme oxygenase-1 inhibition and sigma receptor affinity for anticancer activity. 13th Young Medicinal Chemist's Symposium - Nuove Prospettive in Chimica Farmaceutica. Apr. 26-29, **2021**. P15, *Poster presentation*.
- **Intagliata, S.**; Loredana, S.; Pittalà, V.; Modica, M.N.; Arena, E.; Wilson, L.L.; McLaughlin, J.P.; Prezzavento, O.; Romeo, G. New benzylpiperazine derivatives as selective σ_1 receptor ligands: synthesis, in vitro and in vivo pharmacological characterization. Italian Young Medicinal Chemistry Virtual Meeting. July 22-24, **2020**. PO26. *Poster presentation*.
- Barbaraci, C.; Dichiarà, M.; Fallica, A.N.; Ciaffaglione, V.; **Intagliata, S.**; Marrazzo, A. Sigma-HDACi hybrid molecules as potential therapeutic treatment for uveal melanoma: design, synthesis and preliminary results. Workshop della Sezione Sicilia, SCI 2020. Dec. 3, **2020**, Messina, Italia. OC9. *Oral presentation*.
- Fallica, A.N.; Ciaffaglione, V.; **Intagliata, S.**; Barbaraci, C.; Dichiarà, M.; Sorrenti, V.; Pittalà, V. Targeting the heme oxygenase system with novel azole-based inhibitors possessing an amide function. Workshop della Sezione Sicilia, SCI 2020. Dicembre 3, **2020**, Messina, Italia. P13. *Poster presentation*.
- **Intagliata, S.**; Loredana, S.; Pittalà, V.; Modica, M.N.; Arena, E.; Wilson, L.L.; McLaughlin, J.P.; Prezzavento, O.; Romeo, G. New benzylpiperazine derivatives as selective σ_1 receptor ligands: synthesis, in vitro and in vivo pharmacological characterization. Italian Young Medicinal Chemistry Virtual Meeting (#IYMCVMEET). July 22-24, **2020**. PO26. *Poster presentation*.
- Fallica, A. N.; Pittalà, V.; Rescifina, A.; Ciaffaglione, V.; **Intagliata, S.**; Floresta, G.; Rational design and synthesis of heme oxygenase 2 (HO-2) inhibitors by targeting the secondary hydrophobic pocket of the HO-2 western region. Italian Young Medicinal Chemistry Virtual Meeting (#IYMCVMEET). July 22-24, **2020**. P39. *Poster presentation*.
- Salerno, L.; **Intagliata, S.** Inhibition of heme oxygenase-1 to improve cancer therapy. The 24th World Congress on Advances in Oncology, and 24th International Symposium on Molecular Medicine. Oct. 10-12, **2019**, Sparta, Greece. S48, 273. *Oral presentation*.
- **Intagliata, S.**; Wilson, L.; Alleyne, A.; Stacy, H.M.; Kamble, S.H.; Sharma, A.; Cano, J.; Kawesa, T.; Toll, L.; Avery, B.A.; McLaughlin, J.P.; McCurdy, C.R. Discovery of new 6-substituted-2(3*H*)-benzothiazolones and 6-substituted-2(3*H*)-benzoxazolones: novel σ Rs ligands to treat neuropathic pain. EFMC-ACSMEDI Frontiers 2019- Joint symposium on Medicinal Chemistry Frontiers, June 10-13, **2019**, Cracovia, Poland. PO34. *Poster presentation*.
- Obeng, S.; **Intagliata, S.**; Mottinelli, M.; Restrepo, L.F.; Patel, A.; Wilson, L. L.; Taylor, V. A.; Reeves, M. E.; Pennington, A. E.; McCurdy, C. R.; McMahon, L. R.; Hiranita T. CM304 a sigma1 receptor antagonist enhances the antinociceptive effects of the cannabinoid receptor agonist CP55,940 but not that of morphine in mice. 11th Annual Behavior, Biology, and Chemistry: Translational Research in Addiction. Mar. 2-3, **2019**, San Antonio, Texas, USA, Poster 38. *Poster presentation*.
- Leonardi, C.; Pittalà, V.; Ciaffaglione, V.; Fallica, A. N.; **Intagliata, S.**; Abdelghany, S.; Khalaf, N.B. Computer-aided approach to design protein Leishmania major Disulfide Isomerase (LmPDI) inhibitors. Congresso Congiunto delle Sezioni Sicilia e Calabria 2019. Mar. 1-2, **2019**, Palermo, Italia, P-24. *Poster presentation*.
- Ciaffaglione, V.; Fallica, A. N.; Leonardi, C.; **Intagliata, S.**; Dichiarà, M.; Barbaraci, C.; Carota, G.;

Salerno, L. Development of novel azole-based Heme Oxygenase-1 Inhibitors. Congresso Congiunto delle Sezioni Sicilia e Calabria 2019. Mar. 1–2, **2019**, Palermo, Italia, P-11. *Poster presentation*.

- **Intagliata, S.**; Pittalà, V.; Salerno, L.; Cagnotto, A.; Romeo, G.; Amata, E.; Marrazzo, A.; Modica M.N. New homo and hetero bis-arylpiperazine and bis-benzylpiperazine derivatives as 5-HT₇R selective ligands: design and synthesis. Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry, MedChemSicily, July 17-20, **2018**, Palermo, Italia, P-94. *Poster presentation*.
- Dichiarà, M.; Barbaraci, C.; Gentile, D.; **Intagliata, S.**; Pittalà, V.; Arena, E.; Fraix, A.; Farina, G.; Prezzavento, O.; Amata, E.; Marrazzo A. Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer. Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry, MedChemSicily, July 17-20, **2018**, Palermo, Italia, P-52. *Poster presentation*.
- Montenegro, L.; **Intagliata, S.**; Salerno, L.; Romeo, G.; Pittalà, V.; Siciliano, E.; Panico, A.M.; Modica M.N. Synthesis and in vitro antioxidant activity of a novel idebenone ester with pyroglutamic acid. Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry, MedChemSicily, July 17-20, **2018**, Palermo, Italia, P-71. *Poster presentation*.
- **Intagliata, S.**; Kopajtic, T.A.; Katz, J. L.; Ganno, M. L.; Sharma, A.; Avery, B.A.; Eans, S.O.; McLaughlin, J.P.; McCurdy, C.R. Multidisciplinary Approach in the Optimization of a Highly Selective Sigma-1 Receptor Antagonist. International Narcotic research Conference. June 12-16, **2018**, San Diego, California, USA. P-33. *Poster presentation*.
- Montenegro, L.; Salerno, L.; Romeo, G.; Pittalà, V.; **Intagliata, S.**; Macaluso, B.; Panico, A.M.; Crascì, L.; Modica, M.N. Caratterizzazione chimico-fisica ed attività antiossidante in vitro del triestere trans-resveratrolo trolox. Congresso Congiunto delle Sezioni Sicilia-Calabria 2018. Feb. 9-10, **2018**, Catania, Italy, P09. *Poster presentation*.
- **Intagliata, S.**; Kopajtic, T.A.; Katz, J. L.; Ganno, M. L.; Sharma, A.; Avery, B.A.; Eans, S.O.; McLaughlin, J.P.; McCurdy, C.R. Investigation of Structure Activity Relationships in the Optimization of a Highly Selective Sigma-1 Receptor Antagonist. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. Nov. 12-15, **2017**, San Diego, California, USA, P-M7047. *Poster presentation*.
- Modica, M.N.; Salerno, L.; **Intagliata, S.**; Romeo, G.; Pittalà, V.; Panico, A.M.; Crascì, L.; Puglisi, G.; Montenegro, L. Attività antiossidante in vitro di derivati dell'idebenone. Workshop delle sezioni Sicilia-Calabria SCI, Feb. 9-10, **2017**, Messina, Italia, CO-13. *Oral presentation*.
- Romeo, G.; Pittalà, V.; Salerno, L.; Modica, M.N.; Candido, M.; **Intagliata, S.**; Marrazzo, A.; Amata, E.; Cagnotto, A.; Salmona, M.; Siracusa, M.A. Novel selective ligands for the serotonergic 5-HT₇ receptor: tricyclic derivatives bearing the pyrimido-4(3H)-one ring. XXIV NMMC & 10th NPCF. Sept. 11-14, **2016**, Perugia, Italia, PC-131. *Poster presentation*.
- Romeo, G.; Modica, M.N.; Salerno, L.; Pittalà, V.; **Intagliata, S.**; Cagnotto, A.; Salmona, M.; Siracusa, M.A. Thieno[3,2-*d*]pyrimidine as a scaffold for 5-HT₇ receptor ligands. XXV Congresso della Società Chimica Italiana. SCI-2014. Sept. 7-12, **2014**, Arcavacata di Rende, Cosenza, Italia, P-370. *Poster presentation*.
- Modica, M.N.; **Intagliata, S.**; Romeo, G.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A. New thienopyrimidine and quinazoline derivatives as potential 5-HT₇ receptor ligands. Polish-Austrian-Czech-Germany-Greek-Hungarian-Italian-Slovak-Slovenian VIIIth Joint Meeting on Medicinal Chemistry, Lublin, Poland, June 30-July 4, **2013**, P-31. *Poster presentation*.

TEACHING ACTIVITIES

Academic Year 2024/2025 – Course lecturer of “Laboratorio di Biotecnologie Farmaceutiche, corso A-L, code: 9797680 (S.S.D. CHEM-07/A, 6 CFU)”. Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche – 4° anno, Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania

Academic Year 2024/2025 – Present – Course lecturer of “Laboratorio di Biotecnologie Farmaceutiche, corso M-Z, code: 9797680 (S.S.D. CHEM-07/A, 6 CFU)”. Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche – 4° anno, Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania

Academic Year 2019/2020 – 2023/2024 – Course lecturer of “Laboratorio di Biotecnologie Farmaceutiche, c.i., corso M-Z, code: 1014181 (S.S.D. CHIM/08, 6 CFU)”. Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche – 5° anno, Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania

Academic Year 2019/2020 – 2023/2024 – Course lecturer of “Analisi dei Farmaci e dei Prodotti per la Salute I, c.i., corso A-L, code: 9797718 (S.S.D. CHIM/08, 6 CFU)”. Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche – 5° anno, Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania

MENTORING AND PhD SUPERVISION

- From March 2025 – Present: Supervisor of volunteer research assistant, Ms. Sara Mocka. Project: HO-Hybrid2 project (code: P2022F4PTE) – funded by the European Union – Next Generation EU, PRIN 2022 PNRR program (D.D. 1409 del 14/09/2022 MUR).
- Academic years 2019/2021: Co-supervisor of the Ph.D. thesis entitles “Modulation of heme oxygenase-1 activity by novel synthetic compounds for pharmacological applications.” Ph.D. student: Valeria Ciaffaglione, Dottorato Internazionale in Scienze Chimiche, XXXIV ciclo, Università degli Studi di Catania.
- From 2019 – Present: Supervisor of 8 experimental Master’s theses (Laurea Magistrale in Farmacia and CTF).
- From 2014 – Present: Co-supervisor of 7 experimental Master’s theses (Laurea Magistrale in Farmacia and CTF).

INSTITUTIONAL ROLES

- Sep. 2024 – present: Board Member of the International Ph.D School in Chemical Sciences, cycle XL, University of Catania.
- Jul. 2023 – present: Qualified person for the NMR 500 Varian instrument of the Department of Chemical Sciences of the University of Catania.
- Mar. 2023 – present: Member of the Management Group for Quality Assurance of the Degree Course in CTF, appointed by the board on 03/27/2023.
- Jul. 2022 – present: Member of the management committee for the NMR instrumentation of the Department of Drug and Health Sciences, University of Catania, University of Catania, Italy, DSFS, Unict.
- Nov. 2021 – present: Member of the working group for the Internationalization mobility of the Department of Drug and Health Sciences, University of Catania, University of Catania, Italy.

EDITORIAL ACTIVITY

- Jul. 2025 – present: Member of the Early Career Editorial Board of Molecules, MDPI AG, Basel, Switzerland, (JCR - Q2 Chemistry, Multidisciplinary/ CiteScore - Q1 Chemistry, miscellaneous; IF 2024 = 4.6). ISSN: 1420-3049.

- Guest Editor for the Special Issue entitled "New Strategies and Approaches in Polypharmacology" of *Molecules*, Medicinal Chemistry section, MDPI AG, Basel, Switzerland, (JCR - Q2 Chemistry, Multidisciplinary/ CiteScore - Q1 Chemistry, miscellaneous; IF 2021 = 4.927). ISSN: 1420-3049.
- Guest Editor for the Special Issue entitled "Hybrid Compounds, Multitarget Ligands, and Conjugate Derivatives as New Targeted Anticancer Agents" of *Molecules*, Medicinal Chemistry section, MDPI AG, Basel, Switzerland, (JCR - Q2 Chemistry, Multidisciplinary/CiteScore - Q2 Chemistry, miscellaneous; IF 2020 = 4.411). ISSN: 1420-3049.

ACTIVITY FOR PEER-REVIEW JOURNALS

Aug. 2024 – Present	Chemistry - An Asian Journal. Wiley-VCH. ISSN: 1861-4728
Jan. 2023 – Present	Pharmaceutics, MDPI AG, Basel, Switzerland. ISSN: 1999-4923
Jul. 2022 – Present	Pharmaceutics, MDPI AG, Basel, Switzerland. ISSN: 1424-8247
Mar. 2022 – Present	ChemMedChem, Wiley-VCH. ISSN: 1860-7179
Jul. 2021 – Present	Journal of Medicinal Chemistry, ACS. ISSN: 0022-2623
May 2021 – Present	Bioorganic & Medicinal Chemistry Letters, Elsevier. ISSN: 0960-894X
Dec. 2019 – Present	Biomolecules, MDPI AG, Basel, Switzerland. ISSN 2218-273X
Jul. 2019 – Present	Eur. J. Med. Chem. Elsevier. ISSN: 0223-5234
Jan. 2019 – Present	Molecules, MDPI AG, Basel, Switzerland. ISSN 1420-3049
Apr. 2018 – Present	Medicinal Chemistry Research, Springs. ISSN: 1054-2523
Apr. 2017 – Present	Bioorganic & Medicinal Chemistry, Elsevier. ISSN: 0968-0896
Oct. 2016 – Present	Med. Chem. Comm., Royal Society of Chemistry. ISSN: 2040-2503
Dec. 2016 – Present	Letters in Organic Chemistry, Bentham Science. ISSN: 1570-1786

AWARDS

Apr. 2019	Winner best oral presentations, PostDoc category. CNPD3 UF Drug Discovery Symposium 2019. Gainesville, FL, USA. April 25-26, 2019 .
Mar. 2019	EFMC Grant to attend EFMC-ACSMEDI MedChem Frontiers 2019, Joint Symposium on Medicinal Chemistry Frontiers, Krakow, Poland, June 10-13, 2019 .
Jun. 2018	INRC Travel Award. International Narcotic Research Conference, 2018 Annual meeting, San Diego, CA, USA, June 12-16, 2018 .
Sept. 2014	Travel Award. XXV National Meeting of the Italian Chemical Society, SCI-2014. September 7-12, 2014 . Arcavacata di Rende, Cosenza, Italy.

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

Jun. 2018 – Present	ACS Division of Medicinal Chemistry (ACS MEDI).
Sept. 2017 – Present	American Association of Pharmaceutical Sciences (AAPS).
Feb. 2017 – Present	National Postdoctoral Association (NPA).
July 2014 – Present	Division of Medicinal Chemistry of the Italian Chemical Society.

Last update: 16/07/2025.